TrialBlood advances2021

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia.

Hasmukh Jain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.